185 related articles for article (PubMed ID: 32127832)
21. Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials.
Moon S; Lee J; Chung HS; Kim YJ; Yu JM; Yu SH; Oh CM
Endocrinol Metab (Seoul); 2021 Jun; 36(3):647-660. PubMed ID: 34139800
[TBL] [Abstract][Full Text] [Related]
22. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
O'Neil PM; Aroda VR; Astrup A; Kushner R; Lau DCW; Wadden TA; Brett J; Cancino AP; Wilding JPH;
Diabetes Obes Metab; 2017 Nov; 19(11):1529-1536. PubMed ID: 28386912
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.
Dutta D; Nagendra L; Joshi A; Krishnasamy S; Sharma M; Parajuli N
Obes Surg; 2024 May; 34(5):1653-1664. PubMed ID: 38502519
[TBL] [Abstract][Full Text] [Related]
24. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
Papamargaritis D; Al-Najim W; Lim J; Crane J; Lean M; le Roux C; McGowan B; O'Shea D; Webb D; Wilding J; Davies MJ
BMJ Open; 2020 Feb; 10(2):e034137. PubMed ID: 32060156
[TBL] [Abstract][Full Text] [Related]
26. The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.
von Scholten BJ; Ørsted DD; Svendsen AL; Persson F; Rossing P
J Diabetes Complications; 2015; 29(8):1146-51. PubMed ID: 26345339
[TBL] [Abstract][Full Text] [Related]
27. Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.
Long Y; Zhang Y
Ir J Med Sci; 2023 Dec; 192(6):2809-2814. PubMed ID: 37036569
[TBL] [Abstract][Full Text] [Related]
28. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials.
Wang L; Xin Q; Wang Y; Chen Z; Yuan R; Miao Y; Zhang G; Cong W
Pharmacol Res; 2021 Sep; 171():105765. PubMed ID: 34252552
[TBL] [Abstract][Full Text] [Related]
30. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
[TBL] [Abstract][Full Text] [Related]
31. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.
Zhao X; Huang K; Zheng M; Duan J
BMC Endocr Disord; 2019 Jan; 19(1):4. PubMed ID: 30616638
[TBL] [Abstract][Full Text] [Related]
32. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
Kim SH; Liu A; Ariel D; Abbasi F; Lamendola C; Grove K; Tomasso V; Reaven G
Diabetologia; 2014 Mar; 57(3):455-62. PubMed ID: 24326527
[TBL] [Abstract][Full Text] [Related]
34. The Current Role of Liraglutide in the Pharmacotherapy of Obesity.
Christou GA; Katsiki N; Kiortsis DN
Curr Vasc Pharmacol; 2016; 14(2):201-7. PubMed ID: 26074046
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.
le Roux C; Aroda V; Hemmingsson J; Cancino AP; Christensen R; Pi-Sunyer X
Obes Facts; 2017; 10(6):531-544. PubMed ID: 29145215
[TBL] [Abstract][Full Text] [Related]
36. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
[TBL] [Abstract][Full Text] [Related]
37. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.
Sharma A; Ambrosy AP; DeVore AD; Margulies KB; McNulty SE; Mentz RJ; Hernandez AF; Michael Felker G; Cooper LB; Lala A; Vader J; Groake JD; Borlaug BA; Velazquez EJ
ESC Heart Fail; 2018 Dec; 5(6):1035-1043. PubMed ID: 30120812
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ; Bodicoat DH
PLoS One; 2015; 10(6):e0126769. PubMed ID: 26121478
[TBL] [Abstract][Full Text] [Related]
39. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial.
Gudbergsen H; Overgaard A; Henriksen M; Wæhrens EE; Bliddal H; Christensen R; Nielsen SM; Boesen M; Knop FK; Astrup A; Rasmussen MU; Bartholdy C; Daugaard CL; Ellegaard K; Heitmann BL; Bartels EM; Danneskiold-Samsøe B; Kristensen LE
Am J Clin Nutr; 2021 Feb; 113(2):314-323. PubMed ID: 33471039
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
